Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
too quiet maybe for a very good reason as stated in their 10-Q, if they are working on a sale to Teva. Dr. Barer is well respected in the industry and as chairman for both companies, he will know how to bring some value back to investors. What is known is that the polymer delivery system has a big future in medicine and Teva wants it, which is why they recently updated their patent to include polymers in their successful drug.
"The Company is in the process of performing analyses of the cumulative unblinded data from the NEWTON 2 study to better understand the basis for this outcome. On April 30, 2018, the Company announced that it is currently exploring strategic alternatives, which may include, without limitation, an acquisition of another company, acquisitions or in-licensing of products or product candidates, technologies or other assets, the sale of all or substantially all of the assets of the Company, a sale of stock, a strategic merger or other business combination transaction or other transaction between the Company and a third party."
Teva got granted a revision to their Olanzapine patent in early 2017, which includes the method of utilizing polymers. Maybe Teva might be interested in obtaining Edge’s polymer delivery system. After all, Dr. Barer became Teva’s Chairman also in early 2017 and first thing he did was to hire Rosemary Crane to the board. Both are also BOD for Edge, Dr. Barer is also their chairman. It seems they do have options.
https://patents.google.com/patent/US20170079985A1/en
know what they own, a drug delivery platform that can be utilized in many ways and has a great future ahead due to the need of lowering health costs. If they wanted to, with the cash on hand and the patent for this technology, they can sell the company at a much higher price that current share price. https://www.coherentnews.com/nano-silicon-drug-delivery-platform-market-how-the-market-will-witness-substantial-growth-in-the-upcoming-years/
If you took the time to read over this board you should first take the time to read over the company's web site and find out what is it that they own before making statements that include BK as an option. They own at least $60 million after debt together with a drug delivery system which has been researched and is safe to use. The phase 3 study of their drug did not satisfied the end points, maybe because it was a faulty study since phase 2 had no troubles. Start from there.
looking at the chart, the two last candles had almost the same low, a possible tweezers bottom reversal building. Price could easily open above the last closing price. They also own a delivery system which can be licensed and has worked in the phase2 already. The phase 3 study might have been faulty to its end points, there might be a possibility of doing it again. More news in a month.
they will have 11.2M left over that can be used for an acquisition,
USE OF PROCEEDS
We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $61.2 million, or $70.5 million if
the underwriters fully exercise their option to purchase additional shares, after deducting the underwriting discounts and commissions and estimated offering
expenses payable by us.
The principal purpose of this offering is to further increase our financial flexibility. We currently expect to use the net proceeds from this offering as
follows:
• approximately $30.0 million for clinical development and regulatory activities for clinical products developed from our Orascovery platform;
• approximately $10.0 million for clinical development and regulatory activities for clinical products developed from our Src Kinase Inhibition
platform;
• approximately $10.0 million for other clinical and pre-clinical research and development activities; and
• the remainder for working capital, capital expenditures and general corporate purposes.
We may use a portion of the net proceeds of this offering for the acquisition or licensing, as the case may be, of additional technologies, other assets or
businesses, or for other strategic investments or opportunities, although we have no definitive understandings, agreements or commitments to do so as of the
date hereof.
I am going to share some information that I have gathered over the weekend, which makes me think the company is about to be sold.
On August 28, 2016 Delcath (DCTH) informed shareholders of a plan to extinguish their convertible notes from a majority holder. The purpose for that was to allow them to raise money since cash at hand would only last them until end of January 2018. I think it was probably done so investors who own those notes can participate in an acquisition as majority shareholders, but this is just my speculation. First they needed to reduce shares, so they made a reverse split on November 16 with the excuse of increasing share price, while raising money by exiting those convertible notes on December 28. Days prior to that, on November 20, they appointed Dr. Simon Pedder to the board.
Dr. Pedder also works for Athenex where he is Chief Business and Strategy Officer of Proprietary Products. Entering the board of a target company is done when a suitor has intentions of an acquisition. Dr. Pedder has previously worked with Athenex’s CEO and Chairman, Johnson Y.N. Lau, in a company which was founded by Dr. Pedder and sold in 2014. I benefited from that transaction, since I was a shareholder of that company back then. I believe the two decided to work together again and are now planning to take over Delcath at a very low price. Today Athenex closed a $61.2 million offering which they plan to use portion of the money for an acquisition. My guess is that it will be DCTH.
Athenex is a global biopharmaceutical oncology company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Delcath owns a method to deliver, through a minimally invasive procedure known as percutaneous hepatic perfusion (PHP), directed high dose chemotherapy to the liver. It is approved in Europe and is in Phase 3 study here in the US, which is expected to finish in the beginning of 2019. The FDA should approve it since there are no better alternatives and patients need any help that can extend their lives by months. You can read more about the procedure here: https://doctorlib.info/therapy/embolization-therapy-principles-clinical-applications/42.html
The conclusion to that paper is what’s important to Athenex:
“Collectively, these data provide evidence of clinical benefit for PHP in patients with unresectable metastatic melanoma in the liver, for which there are no suitable alternative therapies for ocular melanoma and emerging therapies of limited effectiveness for cutaneous melanoma. PHP treatment of this patient population is able to alter the disease course, as evidenced by the highly consistent, statistically significant, and clinically meaningful benefits seen with PHP treatment across efficacy end points in the pivotal phase 3 study. The most common grade 3/4 adverse events were thrombocytopenia and anemia. Postprocedure (in-cycle) neutropenia was common but can be mitigated by prophylactic use of growth factors. Recent improvements in the design of the device (Gen 2), procedural technique, and medical management indicate improved safety in European use that needs to be documented through registries and future randomized controlled clinical trials. The periprocedural and postprocedural toxicities associated with melphalan/PHP treatment need to be balanced against the natural course of metastatic melanoma with liver-dominant disease, the large unmet medical need for these patients, and the ability of PHP treatment to potentially alter the disease course.”
In addition to the interest of a future FDA approved therapy for liver cancer, Delcath has intentions to submit application in China as well and has patents for it. Athenex happens to have manufacturing facilities both in US and China. This supports more my reasoning to believe that Delcath will be bought out by Athenex.
So according to you, savvy investors would rather short companies that have been trading at their bottom and just released very good data from their study. Data that improves on the confidence for the study that can lead to a future fast track approaval.
That would not be very smart on their part and not a savvy thing to do. Which is why I consider myself savvy, because I did the opposite of shorting and benefited by trusting my extensive research.
And the best part of it is, with such a low market cap, there is still alot more room for growth.
Savvy investors know when there is a bottom, they know better than to short a stock that is about to go up 100%. They use common sense among other tools.
Simple, because you never short at the bottom, thats not savvy, especially when you already have a preview of the results that will be released in a short term. Let me ask, if you had shorted at $1.34 and after two weeks it is now over $2, would you be a successful hedge fund?
I hope you were savvy enough to buy when I told you to buy and followed what a known hedge fund was doing, buying while the price was on the bottom. You never short in the bottom a company with real catalysts.
Did you not read? Why would Point 72 have purchased short at $1.34 with alot more shares as warrants to be exercised at $1.25 after 6 months, right before Oncosec's next major catalyst, the one Merck assisted in. Coincidence? That the same was done with CPXX. By next summer the price will be over five and those shares will quickly be exercised to then profit on the run and afterwards they can do whatever they want with them. So as a savvy investor what should I be doing?
I am a savvy investor, always ahead of the news, and I know that when Hedge Funds who are not long term investors buy shares of a company when the price is at its lowest ever, you should pay attention. Especially if there are catalyst ahead that can transform the microcap into a target for an acquisition. I will give you a great example, Point72 purchases short term (less than a year) for the sole purpose of a future buy out, the same day phase 3 results came out. Ask yourself one simple question, does history repeat itself?
there was a clinical hold of an investigational agent, which lasted two months, I had forgotten the correct information, thank you. What I am trying to refer to is on this article posted in 2016. https://www.statnews.com/2016/08/22/advaxis-amgen-cancer-listeria/
"But in October 2015, the FDA forced Advaxis to halt four trials of AXAL after a patient with end-stage cervical cancer who died of her disease was found to have listeria in her bloodstream. The stock plummeted.
Advaxis submitted a new plan to the FDA, which included administering antibiotics to patients after treatment. Two months later, the FDA lifted the clinical hold.
Advaxis is now recruiting for Phase 3 trials."
thank you daskapital, I am happy for you to be a part of this immunotherapy technology that Oncosec is working on. I think Dr. Pierce knew exactly what type of result to expect, after he had been practically the one who began successfully working with anti PD-1. You are correct about Daniel O'Connor, he made a deal with Merck for Advaxis, but their problems began after a phase3 study was discontinued due to bad results. Advaxis at the time was working in many different types of studies, which probably took a toll on things. Oncosec has only one thing to focus on, electroporation of IL-12, and I believe IL-12 has been studied for many years for a very good reason. Maybe this is its time to shine.
you are correct, Dan did everything he could at the time with Advaxis, even got them a deal, but one of their phase 3 study failed and that's when everything started falling apart. Plus Advaxis had many different types of studies going on at the same time while Oncosec only has one type, electroporation of IL-12, to focus on.
Bottom line is after 3 years of arguing with some in here about the science, Dr.Pierce has been proven right. Why did they doubt him is beyond my comprehension, but I think most of that had to do with an impatient market and shorts taking advantage. Dr.Pierce basically created immunotherapy when no one was listening, I am sure he is enjoying the results. Let's not forget, his name is in patents.
What history, he has been CEO for one day
Dr. Low, here is Adam Feuerstein's input, maybe he might be able to explain the importance of the science better https://www.statnews.com/2017/11/08/oncosec-melanoma-immunotherapy/
Punit was the political major guy with hardly any experience, O'Connor is a lawyer that has proven capable of making deals. The one most important to Oncosec is the one he made between Merck and Advaxis, to utilize Keytruda in a combination with KEYNOTE-046. However, other different studies were being conducted at the same time and things got somewhat backed up, which of course in turn delays cost money. In addition one of their P3 study for testing a type of brain cancer failed. https://www.fool.com/investing/2016/12/15/celldex-therapeutics-incs-biggest-failure-in-2016.aspx
I would imagine this time will be different, since he basically needs to only focus on one major study, which again is with Keytruda, and concentrate the resources on getting the best deal possible from Merck. We all learn from the past.
"which produce even more IL-12, thus driving significant tumor-specific immune responses" that's exactly why IL-12 is so significant in combinations. This new information was released last week demonstrating its importance:
Researchers identify a molecule p40 monomer which is a member of IL-12 group of proteins that facilitate communication between cells that helps cancer stay alive.
"The team saw that when p40 levels dropped, cancer cells died (though lung cancer cells were not affected), and prostate tumors treated with the MAB in the corroborating mouse model shrank significantly. Levels of interferon-gamma (IFN-gamma) protein, which is capable of killing tumor cells on its own, also rose sharply." https://medicalxpress.com/news/2017-10-molecule-cancer-alive-antibody-therapy.html
electrophysiology expected to reach $5,496.6 million by 2019
"According to Transparency Market Research, The global electrophysiology devices market was valued at USD $2,500 million in 2012 and is expected to reach USD $5,496.6 million by 2019, growing at a CAGR of 12.1% from 2013 to 2019. Electrophysiology devices are used in the diagnosis and treatment of those diseases that occur due to abnormal electrical properties of biological cells and tissues. Electrophysiology devices have wide application in the management of cardiac arrhythmias. The market is expected to record growth mainly due to globally rising geriatric population leading to increasing incidence of arrhythmias and advances in technology that has resulted in minimally invasive procedures and improved features."
yes they do, especially the ones Cohen is involved with. I don't know much about hedge funds like most, but I do know that.
was not my comment attached to your lecture? so that would mean that I read it. I thought you knew only science I am surprised you also know hedge funds
I am sorry I don't understand that comment
Frigate Ventures LP discloses 6.50% ownership in ONCS yesterday after they had purchased 227,293 shares on 12/31/2016 and sold them on 3/31/2017, so the question is why come back and buy 1,860,467 shares which is seven times more of what they previously had, and do it right after results of P2? was it the science or the knowledge of price increasing from this point? either way, it is a very good sign from investors that are familiar with the company.
https://fintel.io/soh/us/oncs/frigate-ventures-lp
And as Non responders who have no other option, what does the study mean for those few or for the FDA?
Do you have any idea of the prcedure for a study to get published?
Non responders are responding, that's what matters
What's important are results and so far they have improved tremendously. The market is about money but the science is about helping people, regardless of what some think.
I thought we went through this last night and from your response it seemed you also agreed with the science and the 50% BOOR, you do know that's how the FDA decides at the end if approval or not, especially since they are working very close together now.
you are right, the science is a joke
sorry but it is convincing to those investors that purchased a large amount of shares within a week. Is that better wording?
Maybe those investors do know that a technological disruption will take place with Oncosec, since combinations of immunotherapy are the paths to an approach for the fight on a tumor, but a vehicle is needed for helping with synergetic efficacy and lowering the toxicity and disruption of the immune system. Electroporation of IL-12 is taking care of that.
Reading the first report of electroporation-mediated IL-12 gene therapy done back in 2001, signs of the cytokine's importance was already proven by the eradication of established murine tumors and their metastases, leading to the generation of tumor-specific immunological memory. However, in the first clinical trial, IL-12 protein therapy resulted in the death of 2 patients and led to severe toxic effects in 15 others. http://cancerres.aacrjournals.org/content/61/3/1005
Sixteen years later Oncosec shows results of electroporation IL-12 in a combination therapy with Keytruda, the most important immunotherapy to date. The study yielded a 50% best overall response rate at 24 weeks, with 42.9% of the cohort reaching RECIST v1.1 response. The combination resulted in 41% of patients who were diagnosed as non-responders becoming complete responders, 9% had a partial response, and 9% had stable disease. This accounted for a total disease control rate of 59%. The serious adverse event rate in the combination study was 8.7% with no life-threatening or grade 4 adverse events. That's pretty amazing when compared to other present studies which are not utilizing an assay for assessing the non responders like Oncosec is doing.
I found this article that was published days after Oncosec's results got released. Researchers identify a molecule p40 monomer which is a member of IL-12 group of proteins that facilitate communication between cells that helps cancer stay alive.
"The team saw that when p40 levels dropped, cancer cells died (though lung cancer cells were not affected), and prostate tumors treated with the MAB in the corroborating mouse model shrank significantly. Levels of interferon-gamma (IFN-gamma) protein, which is capable of killing tumor cells on its own, also rose sharply."
https://medicalxpress.com/news/2017-10-molecule-cancer-alive-antibody-therapy.html
This is very good news for Oncosec as it shines a light on the importance of IL-12 cytokine and helps to show why they are on the correct path. The scientist are hoping to bringing p40 to clinical trials but it will take a few years for that. In the mean time Oncosec has fast track designation and will look to qualify for expedited FDA review, and a rolling Biologics License Application (BLA)
Now hopefully more people will know as well, including the cancer patients.
according to you, yes, else why the question? "LOL LOL,so I should invest because you say so? sorry"
that's only the beginning, I noticed from last week how institutes were buying shares and they have continued doing so up to this week. And that was done without me saying a word to them of why they should buy. I think the science speaks for its own.
they are related, look below under relatives. https://www.mylife.com/mitchell-kopin/e454951875768 Jordyn works in New York at Cogent, so it is her. He knows exactly what he is investing in, since he also has a 5.2% on Celsion. He must really like IL-12 and knows why it will be needed as a base for combinations. However, Oncosec has the advantage of utilizing Electroporation vs their Vector of IL-12 and Oncosec is combining their IL-12 with Keytruda while Celsion is doing it with chemo. Also Oncosec has a more advanced study and a larger stake by Mitchell P. Kopin
so you will miss the last step, because I think different, and so does Cohen with his millions.
of course you have, but would you be right if the company gets sold to Merck? or do you also think that's not a possibility?
you have not seen anything yet